Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

FDA on rosiglitazone. More on advisory committee decision.

Graham DJ, Gelperin K.

BMJ. 2010 Sep 7;341:c4868. doi: 10.1136/bmj.c4868. No abstract available.

PMID:
20823021
[PubMed - indexed for MEDLINE]
2.

The rosiglitazone story--lessons from an FDA Advisory Committee meeting.

Rosen CJ.

N Engl J Med. 2007 Aug 30;357(9):844-6. Epub 2007 Aug 8. No abstract available.

PMID:
17687124
[PubMed - indexed for MEDLINE]
Free Article
3.

Rosiglitazone and the FDA.

Krall RL.

N Engl J Med. 2007 Oct 25;357(17):1776-7; author reply 1777. No abstract available.

PMID:
17969232
[PubMed - indexed for MEDLINE]
4.

Revisiting the rosiglitazone story--lessons learned.

Rosen CJ.

N Engl J Med. 2010 Aug 26;363(9):803-6. doi: 10.1056/NEJMp1008233. Epub 2010 Jul 21. No abstract available.

PMID:
20660395
[PubMed - indexed for MEDLINE]
Free Article
5.

The rosiglitazone decision process at FDA and EMA. What should we learn?

Pouwels KB, van Grootheest K.

Int J Risk Saf Med. 2012;24(2):73-80. doi: 10.3233/JRS-2012-0559.

PMID:
22751189
[PubMed - indexed for MEDLINE]
6.

FDA puts rosiglitazone post-marketing trial on hold.

Cohen D.

BMJ. 2010 Jul 26;341:c4017. doi: 10.1136/bmj.c4017. No abstract available.

PMID:
20660507
[PubMed - indexed for MEDLINE]
7.

FDA advisers recommend new controls on rosiglitazone use.

Traynor K.

Am J Health Syst Pharm. 2010 Aug 15;67(16):1306-8. doi: 10.2146/news100056. No abstract available.

PMID:
20689113
[PubMed - indexed for MEDLINE]
8.

The painful truth.

Nissen SE.

Eur Heart J. 2010 May;31(10):1284-5. doi: 10.1093/eurheartj/ehq126. Epub 2010 Apr 23. No abstract available.

PMID:
20418344
[PubMed - indexed for MEDLINE]
Free Article
9.

FDA hearings leave doctors, patients in limbo on Avandia.

Eggertson L, Woodward C.

CMAJ. 2010 Sep 7;182(12):E559-60. doi: 10.1503/cmaj.109-3321. Epub 2010 Jul 26. No abstract available.

PMID:
20660583
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.

Bourg CA, Phillips BB.

Ann Pharmacother. 2012 Feb;46(2):282-9. doi: 10.1345/aph.1Q400. Epub 2012 Jan 31. Review.

PMID:
22298606
[PubMed - indexed for MEDLINE]
11.

Rosiglitazone, marketing, and medical science.

Moynihan R.

BMJ. 2010 Apr 7;340:c1848. doi: 10.1136/bmj.c1848. No abstract available.

PMID:
20375091
[PubMed - indexed for MEDLINE]
12.

The value equation for rosiglitazone and pioglitazone in older persons.

Zarowitz BJ.

Geriatr Nurs. 2008 Jan-Feb;29(1):9-11. doi: 10.1016/j.gerinurse.2007.11.004. No abstract available.

PMID:
18267172
[PubMed - indexed for MEDLINE]
13.

Rosiglitazone: what went wrong?

Cohen D.

BMJ. 2010 Sep 6;341:c4848. doi: 10.1136/bmj.c4848. No abstract available.

PMID:
20819889
[PubMed - indexed for MEDLINE]
14.

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.

Hiatt WR, Kaul S, Smith RJ.

N Engl J Med. 2013 Oct 3;369(14):1285-7. doi: 10.1056/NEJMp1309610. Epub 2013 Sep 2. No abstract available.

PMID:
23992603
[PubMed - indexed for MEDLINE]
Free Article
15.

FDA committee urges tight restrictions on rosiglitazone.

Roehr B.

BMJ. 2010 Jul 16;341:c3862. doi: 10.1136/bmj.c3862. No abstract available.

PMID:
20639290
[PubMed - indexed for MEDLINE]
16.

Rosiglitazone and the FDA.

Joffe HV, Parks MH, Meyer RJ, Jenkins JK, Temple R.

N Engl J Med. 2007 Oct 25;357(17):1775-6; author reply 1777. Epub 2007 Aug 29. No abstract available.

PMID:
17761586
[PubMed - indexed for MEDLINE]
Free Article
17.

Rosiglitazone: trials, tribulations and termination.

Krentz AJ.

Drugs. 2011 Jan 22;71(2):123-30. doi: 10.2165/11585300-000000000-00000. No abstract available.

PMID:
21275442
[PubMed - indexed for MEDLINE]
18.

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.

PMID:
18693776
[PubMed - indexed for MEDLINE]
Free Article
19.

Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?

Freemantle N.

BMJ. 2010 Sep 6;341:c4812. doi: 10.1136/bmj.c4812. No abstract available.

PMID:
20819888
[PubMed - indexed for MEDLINE]
20.

Clinical consequences of disseminating the rosiglitazone FDA safety warning.

Orrico KB, Lin JK, Wei A, Yue H.

Am J Manag Care. 2010 May 1;16(5):e111-6.

PMID:
20455636
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk